Hepatocellular Carcinoma News and Research

RSS

Hepatocellular Carcinoma is a type of adenocarcinoma, the most common type of liver tumor.

Azvudine beats paxlovid in reducing COVID-19 deaths

In hospitalized COVID-19 patients, azvudine shows lower all-cause mortality and fewer adverse events than Paxlovid, with added antitumor effects observed.

21 Jan 2025

New insights into rare liver cancer as clinical trial for treatment begins

Like many rare diseases, fibrolamellar hepatocellular carcinoma (FLC) mounts a ferocious attack against an unlucky few-in this case, children, adolescents, and young adults.

17 Jan 2025

Exploring the role of EpCAM in early-stage hepatocellular carcinoma progression

Announcing a new publication for Acta Materia Medica journal. Epithelial cell adhesion molecule (EpCAM) is a biomarker for epithelial cell-derived tumors.

17 Jan 2025

Alcohol consumption increases risks of cirrhosis and HCC in patients with HBV infection

The quantitative effects of alcohol consumption on cirrhosis and hepatocellular carcinoma (HCC) in hepatitis B virus (HBV) infection are unknown.

16 Jan 2025

RNA nanoparticles offer dual action against prostate tumors

Yang Zhang, PhD, and Jinjun Shi, PhD, both of the Center for Nanomedicine and Department of Anesthesiology, Perioperative and Pain Medicine at Brigham and Women's Hospital, are co-senior authors of a paper published in ACS Nanoscience Au, "Lipid Nanoparticle Delivery of mRNA and siRNA for Concurrent Restoration of Tumor Suppressor and Inhibition of Tumorigenic Driver in Prostate Cancer."

10 Jan 2025

Study reveals how fatty liver disease leads to liver cancer

Scientists at University of California San Diego School of Medicine have shed new light on the development of liver cancer, the sixth most frequently diagnosed cancer and fourth leading cause of cancer deaths worldwide.

2 Jan 2025

Investigating fatty acid metabolism in hepatocellular carcinoma patients

Announcing a new publication for Acta Materia Medica journal. Fatty acid (FA) reprogramming has a significant role in liver cancer. However, the contribution of FA metabolism reprogramming to the heterogeneity of hepatocellular carcinoma (HCC) has not been established.

30 Dec 2024

Adding SBRT to sorafenib improves survival in hepatocellular carcinoma patients

Recent results from the Phase III NRG-RTOG 1112 clinical study showed that the addition of stereotactic body radiotherapy (SBRT) to systemic therapy with sorafenib significantly improved progression-free survival (PFS) and time-to-progression in patients with locally advanced hepatocellular carcinoma (HCC) when compared to sorafenib alone.

20 Dec 2024

Dual screening for liver fibrosis and retinopathy in type 2 diabetes

Retina scanning with vibration-controlled transient elastography could predict metabolic dysfunction-associated steatotic liver disease.

17 Dec 2024

Promising combination therapy could improve liver cancer outcomes

Dan G. Duda, DMD, PhD, of the Edwin L. Steele Laboratories for Tumor Biology and Department of Radiation Oncology at Massachusetts General Hospital, is the corresponding author of a paper published in Cancer Immunology Research, "Combination CXCR4 and PD1 Blockade Enhances Intratumoral Dendritic Cell Activation and Immune Responses Against Hepatocellular Carcinoma."

14 Dec 2024

Exosomes: A double-edged sword in hepatocellular carcinoma

The TIME is a dynamic network composed of cancer cells, immune cells, and stromal components. During the early stages of tumorigenesis, the TIME attempts to eliminate abnormal cells through immune surveillance.

11 Dec 2024

TCR sequencing sheds light on tumor immune interactions in hepatocellular carcinoma

Hepatocellular carcinoma (HCC) stands as the dominant form of liver cancer, ranking as the fourth leading cause of cancer-related deaths globally.

11 Dec 2024

Scientists link proteins to Alzheimer’s through cutting-edge genetic method

Researchers have developed MR-SPI, a novel method integrated with AlphaFold3, to identify causal protein biomarkers and predict their 3D structural changes in Alzheimer’s disease. This breakthrough offers insights into disease mechanisms and potential therapeutic targets.

5 Dec 2024

Disrupted sleep-wake rhythms linked to liver disease progression

The prevalence of MASLD (metabolic dysfunction-associated steatotic liver disease) is exploding in most regions of the world, boosted by increased obesity and sedentary lifestyles. MASLD (formerly known as non-alcoholic fatty liver disease) is already the most common liver disorder: it affects 30% of adults and between 7% and 14% of children and adolescents, and this prevalence is predicted to rise to more than 55% of adults by 2040.

4 Dec 2024

A roadmap for improving cancer care in South Asia

A series of five papers, published today in The Lancet Oncology by a University of Pittsburgh-led international team, highlights critical public health challenges related to cancer control in the eight countries that form the South Asian Association for Regional Cooperation (SAARC) and the Rohingya refugee population in Bangladesh.

3 Dec 2024

Disrupted sleep patterns identified in patients with metabolic dysfunction-associated steatotic liver disease

The prevalence of MASLD (metabolic dysfunction-associated steatotic liver disease) is exploding in most regions of the world, boosted by increased obesity and sedentary lifestyles.

2 Dec 2024

Mursla Bio's EvoLiver surpasses current standards in liver cancer surveillance, data presented at AASLD Liver Meeting 2024

Mursla Bio, a leader in Extracellular Vesicle (EV) science on a mission to significantly improve cancer outcomes for at-risk patients through the power of dynamic biopsy technology, today announced results of its multi-center clinical study, MEV01, in collaboration with leading academic institutes including University College London, Imperial College London, University Hospital of Santa Maria and the Medical University of Graz.

From Mursla Bio 25 Nov 2024